These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38649304)

  • 1. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong
    Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
    J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.
    Wu T; Hu J; Zhao X; Zhang C; Dong R; Hu Q; Xu H; Shen H; Zhang X; Zhang Y; Lin B; Wu X; Xiang Q; Xu Y
    J Med Chem; 2024 Jun; 67(11):9194-9213. PubMed ID: 38829718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of new RNF126-based p300/CBP degraders.
    Lei YH; Tang Q; Ni Y; Li CH; Luo P; Huang K; Chen X; Zhu YX; Wang NY
    Bioorg Chem; 2024 Jul; 148():107427. PubMed ID: 38728911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
    Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma.
    Chang Q; Li J; Deng Y; Zhou R; Wang B; Wang Y; Zhang M; Huang X; Li Y
    J Med Chem; 2024 Feb; 67(4):2466-2486. PubMed ID: 38316017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.
    Thomas JE; Wang M; Jiang W; Wang M; Wang L; Wen B; Sun D; Wang S
    J Med Chem; 2023 Jun; 66(12):8178-8199. PubMed ID: 37276143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
    Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
    J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CBP and p300: Emerging Anticancer Agents.
    Masci D; Puxeddu M; Silvestri R; La Regina G
    Molecules; 2024 Sep; 29(19):. PubMed ID: 39407454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
    Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
    Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
    Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
    Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.
    Yin S; Kaluz S; Devi NS; Jabbar AA; de Noronha RG; Mun J; Zhang Z; Boreddy PR; Wang W; Wang Z; Abbruscato T; Chen Z; Olson JJ; Zhang R; Goodman MM; Nicolaou KC; Van Meir EG
    Clin Cancer Res; 2012 Dec; 18(24):6623-33. PubMed ID: 22923450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
    Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
    J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors.
    Bi X; Chen Y; Sun Z; Lu W; Xu P; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127480. PubMed ID: 32882416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
    Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
    Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases.
    Ji Z; Clark RF; Bhat V; Matthew Hansen T; Lasko LM; Bromberg KD; Manaves V; Algire M; Martin R; Qiu W; Torrent M; Jakob CG; Liu H; Cole PA; Marmorstein R; Kesicki EA; Lai A; Michaelides MR
    Bioorg Med Chem Lett; 2021 May; 39():127854. PubMed ID: 33631370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
    Picaud S; Fedorov O; Thanasopoulou A; Leonards K; Jones K; Meier J; Olzscha H; Monteiro O; Martin S; Philpott M; Tumber A; Filippakopoulos P; Yapp C; Wells C; Che KH; Bannister A; Robson S; Kumar U; Parr N; Lee K; Lugo D; Jeffrey P; Taylor S; Vecellio ML; Bountra C; Brennan PE; O'Mahony A; Velichko S; Müller S; Hay D; Daniels DL; Urh M; La Thangue NB; Kouzarides T; Prinjha R; Schwaller J; Knapp S
    Cancer Res; 2015 Dec; 75(23):5106-5119. PubMed ID: 26552700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents.
    Wei J; Yang Y; Lu M; Lei Y; Xu L; Jiang Z; Xu X; Guo X; Zhang X; Sun H; You Q
    Mini Rev Med Chem; 2018; 18(4):296-309. PubMed ID: 27484627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
    Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
    Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Dual-Site Inhibitor of CBP/p300 KIX is a Selective and Effective Modulator of Myb.
    Joy ST; Henley MJ; De Salle SN; Beyersdorf MS; Vock IW; Huldin AJL; Mapp AK
    J Am Chem Soc; 2021 Sep; 143(37):15056-15062. PubMed ID: 34491719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.